Overview & History

Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.

Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional €18.2M raised from blue chip investors in the US and Europe in March 2017.

The company has a broad and growing portfolio, with two compounds in clinical trials, Iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor for the treatment of multiple sclerosis, Alzheimer’s disease and other neurodegenerative diseases, in Phase IIA, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications.

From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY-2001) since the start of our CNS research.

The company has a seasoned executive management with vast experience in the industry.